Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Platelet biology

Charles S Abrams, MD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


The platelet is a circulating anucleate disc-shaped cell, responsible for initiation of the hemostatic mechanisms that repair injury to the vascular endothelium. The four major platelet functions include the following (figure 1):

Platelet adherence

Platelet activation and secretion

Platelet aggregation [1]

Interaction with coagulation factors


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 28, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109:5087.
  2. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7:1759.
  3. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004; 104:1606.
  4. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112:3011.
  5. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64:1393.
  6. Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88:907.
  7. Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol Chem 2000; 381:389.
  8. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389:183.
  9. Yang J, Wu J, Jiang H, et al. Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 2002; 277:46035.
  10. Moers A, Nieswandt B, Massberg S, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003; 9:1418.
  11. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64:1057.
  12. Brass LF, Vassallo RR Jr, Belmonte E, et al. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992; 267:13795.
  13. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304:855.
  14. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86:189.
  15. Holtkötter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277:10789.
  16. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318:470.
  17. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84:1440.
  18. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16:2333.
  19. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104:1350.
  20. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139:363.
  21. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3:175.
  22. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121:171.
  23. Cunningham MR, Nisar SP, Mundell SJ. Molecular mechanisms of platelet P2Y(12) receptor regulation. Biochem Soc Trans 2013; 41:225.
  24. Cattaneo M. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117:2102.
  25. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:202.
  26. Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36:1394.
  27. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429.
  28. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119:2553.
  29. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008; 156:S16.
  30. Yang J, Wu J, Kowalska MA, et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A 2000; 97:9984.
  31. Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J Biol Chem 1983; 258:11236.
  32. Cockcroft S, Thomas GM. Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J 1992; 288 ( Pt 1):1.
  33. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361:315.
  34. Brass LF, Manning DR, Williams AG, et al. Receptor and G protein-mediated responses to thrombin in HEL cells. J Biol Chem 1991; 266:958.
  35. Lapetina EG, Billah MM, Cuatrecasas P. Lysophosphatidic acid potentiates the thrombin-induced production of arachidonate metabolites in platelets. J Biol Chem 1981; 256:11984.
  36. Rittenhouse SE, Sasson JP. Mass changes in myoinositol trisphosphate in human platelets stimulated by thrombin. Inhibitory effects of phorbol ester. J Biol Chem 1985; 260:8657.
  37. Lian L, Wang Y, Flick M, et al. Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood 2009; 113:3577.
  38. Kaibuchi K, Takai Y, Sawamura M, et al. Synergistic functions of protein phosphorylation and calcium mobilization in platelet activation. J Biol Chem 1983; 258:6701.
  39. Brass LF, Joseph SK. A role for inositol triphosphate in intracellular Ca2+ mobilization and granule secretion in platelets. J Biol Chem 1985; 260:15172.
  40. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655.
  41. Chen J, De S, Damron DS, et al. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 2004; 104:1703.
  42. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15:2019.
  43. Watanabe N, Nakajima H, Suzuki H, et al. Functional phenotype of phosphoinositide 3-kinase p85alpha-null platelets characterized by an impaired response to GP VI stimulation. Blood 2003; 102:541.
  44. Lian L, Wang Y, Draznin J, et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood 2005; 106:110.
  45. Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. J Thromb Haemost 2009; 7:1057.
  46. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost 2010; 8:454.
  47. Abrams CS, Kazanietz MG. Cambridge University Press. In: Platelets in Thrombotic and Non-Thrombotic Disorders, Gresele P, Page C, Fuster V, Vermylen J (Eds), Cambridge, UK 2002. p.272.
  48. Vane JR. Biomedicine. Back to an aspirin a day? Science 2002; 296:474.
  49. Stanford N, Roth GJ, Shen TY, Majerus PW. Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins 1977; 13:669.
  50. Thomas P, Hepburn B, Kim HC, Saidi P. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol 1982; 12:131.
  51. McIntyre BA, Philp RB, Inwood MJ. Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients. Clin Pharmacol Ther 1978; 24:616.
  52. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449.
  53. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62:1153.
  54. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388:678.
  55. Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003; 112:77.
  56. Lewis GD, Witzke C, Colon-Hernandez P, et al. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. J Am Coll Cardiol 2006; 47:1471.
  57. Schmidt U, Han RO, DiSalvo TG, et al. Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. J Am Coll Cardiol 2001; 37:1981.
  58. Ma AD, Abrams CS. Pleckstrin homology domains and phospholipid-induced cytoskeletal reorganization. Thromb Haemost 1999; 82:399.
  59. Nachmias VT, Yoshida K. The cytoskeleton of the blood platelet; a dynamic structure. Adv Cell Biol 1988; 2:181.
  60. Hartwig JH, Bokoch GM, Carpenter CL, et al. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets. Cell 1995; 82:643.
  61. Italiano JE Jr, Bergmeier W, Tiwari S, et al. Mechanisms and implications of platelet discoid shape. Blood 2003; 101:4789.
  62. Patel-Hett S, Richardson JL, Schulze H, et al. Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111:4605.
  63. Li R, Mitra N, Gratkowski H, et al. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003; 300:795.
  64. Shattil SJ, Ginsberg MH, Brugge JS. Adhesive signaling in platelets. Curr Opin Cell Biol 1994; 6:695.
  65. Coppinger JA, O'Connor R, Wynne K, et al. Moderation of the platelet releasate response by aspirin. Blood 2007; 109:4786.
  66. Reed GL, Fitzgerald ML, Polgár J. Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood 2000; 96:3334.
  67. Huang Y, Joshi S, Xiang B, et al. Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking. Blood 2016; 127:1459.